Should I buy or sell Allakos stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLK shares. View ALLK analyst ratings or view top-rated stocks .

What is Allakos' stock price target for 2024?

7 analysts have issued 1 year price targets for Allakos' stock. Their ALLK share price targets range from $1.50 to $22.00. On average, they anticipate the company's share price to reach $11.36 in the next year. This suggests a possible upside of 333.5% from the stock's current price. View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts .

How have ALLK shares performed in 2023?

Allakos' stock was trading at $8.42 at the start of the year. Since then, ALLK stock has decreased by 68.9% and is now trading at $2.62. View the best growth stocks for 2023 here .

Are investors shorting Allakos?

Allakos saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 3,430,000 shares, a drop of 13.2% from the October 31st total of 3,950,000 shares. Based on an average daily volume of 960,600 shares, the short-interest ratio is presently 3.6 days. View Allakos' Short Interest .

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our ALLK earnings forecast .

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49).

What ETF holds Allakos' stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 22,191 shares of ALLK stock, representing 1.04% of its portfolio.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV) , Advanced Micro Devices (AMD) , Pfizer (PFE) , Agios Pharmaceuticals (AGIO) , Biohaven (BHVN) , bluebird bio (BLUE) , Eastman Chemical (EMN) , Heron Therapeutics (HRTX) , TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS) .

When did Allakos IPO?

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

Who are Allakos' major shareholders?

Allakos' stock is owned by many different retail and institutional investors. Top institutional investors include RiverVest Venture Management LLC (5.74%), Redmile Group LLC (4.76%), Blackstone Inc. (4.71%), Vontobel Holding Ltd. (0.89%), Sectoral Asset Management Inc. (0.89%) and Citigroup Inc. (0.52%). Insiders that own company stock include Adam Tomasi , Daniel Janney , Henrik S Md Rasmussen , Paul Edward Walker, Peter A Hudson , Robert Alexander , Robert J More and Steven P James . View institutional ownership trends .

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Allakos Stock Price, News & Analysis (NASDAQ:ALLK)

$2.62

+0.34 (+14.91%)

(As of 12/4/2023 ET)

Compare

Today's Range: $2.36
▼
$2.65
50-Day Range: $1.72
▼
$2.50
52-Week Range: $1.48
▼
$8.73

Volume: 1.65 million shs
Average Volume: 1.00 million shs
Market Capitalization: $229.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.36

Allakos MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 333.5% Upside
$11.36 Price Target
Short Interest: Healthy
3.92% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.86
Upright™ Environmental Score
News Sentiment: 0.93
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.87) to ($1.84) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.81 out of 5 stars

Medical Sector

51st out of 952 stocks

Pharmaceutical Preparations Industry

11th out of 434 stocks

3.3

Analyst's Opinion

Consensus Rating
Allakos has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $11.36, Allakos has a forecasted upside of 333.5% from its current price of $2.62.
Amount of Analyst Coverage
Allakos has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.92% of the outstanding shares of Allakos have been sold short.
Short Interest Ratio / Days to Cover
Allakos has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Allakos has recently decreased by 13.16%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Allakos does not currently pay a dividend.
Dividend Growth
Allakos does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Allakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Allakos is -0.86.

2.7

News and Social Media Coverage

News Sentiment
Allakos has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Allakos this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for ALLK on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Allakos to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Allakos insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.07% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Allakos are expected to grow in the coming year, from ($1.87) to ($1.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Allakos is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Allakos is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Allakos has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Allakos Stock (NASDAQ:ALLK)

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.

ALLK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALLK Stock News Headlines

November 30, 2023 | americanbankingnews.com

Allakos (NASDAQ:ALLK) Stock Rating Reaffirmed by JMP Securities

November 28, 2023 | markets.businessinsider.com

Buy Rating for Allakos: Anticipating Lirentelimab’s Market Catalyst and Blockbuster Potential

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 16, 2023 | bizjournals.com

Ohio's VC vehicle has attracted investment and jobs – but could cost taxpayers $100M

November 15, 2023 | msn.com

Allakos GAAP EPS of -$0.52 misses by $0.06

November 15, 2023 | markets.businessinsider.com

Promising Developments and Solid Financials Drive Buy Rating for Allakos: An Analysis of Lirentelimab Trials and Investment Potential

November 14, 2023 | finanznachrichten.de

Allakos Inc.: Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

November 14, 2023 | markets.businessinsider.com

TD Cowen Reaffirms Their Hold Rating on Allakos (ALLK)

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 13, 2023 | seekingalpha.com

Allakos files to sell up to $250M worth of its common stock

November 13, 2023 | finance.yahoo.com

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

November 13, 2023 | finance.yahoo.com

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q3 2023

November 6, 2023 | finance.yahoo.com

Following a 63% decline over last year, recent gains may please Allakos Inc. (NASDAQ:ALLK) institutional owners

November 2, 2023 | msn.com

AlloVir GAAP EPS of -$0.39 beats by $0.01

October 5, 2023 | msn.com

Allakos (ALLK) Price Target Increased by 23.96% to 10.12

September 27, 2023 | msn.com

Allokos stock jumps 16% as JMP starts coverage at market outperform

September 27, 2023 | msn.com

Allakos' Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock Upside

September 27, 2023 | finance.yahoo.com

Why Shares of Allakos Are Up Wednesday

September 27, 2023 | markets.businessinsider.com

Promising Prospects for Allakos’ Innovative Monoclonal Antibodies: A Strong Buy Rating

September 18, 2023 | msn.com

Scratching The Surface: Allakos' Novel Take On Urticaria

August 31, 2023 | finanznachrichten.de

Allakos Inc.: Allakos Appoints Neil Graham to its Board of Directors

August 30, 2023 | finance.yahoo.com

Allakos Appoints Neil Graham to its Board of Directors

August 11, 2023 | finanznachrichten.de

Allakos Inc.: Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

August 10, 2023 | markets.businessinsider.com

Goldman Sachs Sticks to Their Hold Rating for Allakos (ALLK)

August 10, 2023 | markets.businessinsider.com

Allakos (ALLK) Initiated with a Sell at Barclays

August 9, 2023 | finance.yahoo.com

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

August 8, 2023 | investing.com

Allakos (ALLK) Earnings Dates & Reports

See More Headlines

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/09/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALLK
CUSIP: N/A
CIK: 1564824
Web: www.allakos.com
Phone: (650) 597-5002
Fax: N/A
Employees: 123
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.36
High Stock Price Target: $22.00
Low Stock Price Target: $1.50
Potential Upside/Downside: +333.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-319,950,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -62.29%
Return on Assets: -49.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.31
Quick Ratio: 9.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.64 per share
Price / Book: 0.72

Miscellaneous

Outstanding Shares: 87,480,000
Free Float: 62,921,000
Market Cap: $229.20 million
Optionable: Not Optionable
Beta: 0.68

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Robert Alexander Ph.D. (Age 53)
CEO & Director
Comp: $1.46M
Dr. Adam L. Tomasi Ph.D. (Age 53)
President
Comp: $1.11M
Mr. Baird Radford III (Age 53)
Chief Financial Officer
Comp: $708.26k
Ms. Mary Cromwell Ph.D.
Chief Technical Officer
Dr. Craig Paterson M.D. (Age 58)
Chief Medical Officer
Mr. Alan Chang
Director of Medical Affairs & Data Analytics

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ALLK Stock Analysis - Frequently Asked Questions

Should I buy or sell Allakos stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLK shares.
View ALLK analyst ratings or view top-rated stocks.
What is Allakos' stock price target for 2024?: 7 analysts have issued 1 year price targets for Allakos' stock. Their ALLK share price targets range from $1.50 to $22.00. On average, they anticipate the company's share price to reach $11.36 in the next year. This suggests a possible upside of 333.5% from the stock's current price.
View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts.
How have ALLK shares performed in 2023?: Allakos' stock was trading at $8.42 at the start of the year. Since then, ALLK stock has decreased by 68.9% and is now trading at $2.62.
View the best growth stocks for 2023 here.
Are investors shorting Allakos?: Allakos saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 3,430,000 shares, a drop of 13.2% from the October 31st total of 3,950,000 shares. Based on an average daily volume of 960,600 shares, the short-interest ratio is presently 3.6 days.
View Allakos' Short Interest.
When is Allakos' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our ALLK earnings forecast.
How were Allakos' earnings last quarter?: Allakos Inc. (NASDAQ:ALLK) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49).

What ETF holds Allakos' stock ?: Virtus LifeSci Biotech Clinical Trials ETF holds 22,191 shares of ALLK stock, representing 1.04% of its portfolio.
What other stocks do shareholders of Allakos own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).
When did Allakos IPO?: (ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.
Who are Allakos' major shareholders?: Allakos' stock is owned by many different retail and institutional investors. Top institutional investors include RiverVest Venture Management LLC (5.74%), Redmile Group LLC (4.76%), Blackstone Inc. (4.71%), Vontobel Holding Ltd. (0.89%), Sectoral Asset Management Inc. (0.89%) and Citigroup Inc. (0.52%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends.
How do I buy shares of Allakos?: Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALLK) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial